Published in J Inherit Metab Dis on June 28, 2012
Quantitation of gamma-hydroxybutyric acid in dried blood spots: feasibility assessment for newborn screening of succinic semialdehyde dehydrogenase (SSADH) deficiency. Mol Genet Metab (2013) 2.06
Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci (2014) 1.01
Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. J Pediatr Epilepsy (2014) 0.89
Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA. Neurology (2014) 0.83
Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem Int (2016) 0.83
Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). Front Hum Neurosci (2013) 0.80
Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification. Dev Med Child Neurol (2014) 0.79
Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse. Ann Clin Transl Neurol (2015) 0.79
Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. Biochim Biophys Acta (2016) 0.77
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors. Curr Top Med Chem (2016) 0.75
Targeted screening of succinic semialdehyde dehydrogenase deficiency (SSADHD) employing an enzymatic assay for γ-hydroxybutyric acid (GHB) in biofluids. Mol Genet Metab Rep (2016) 0.75
Gamma-hydroxybutyric acid. N Engl J Med (2005) 5.81
Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology (1998) 4.01
A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol (1987) 1.89
The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics (1997) 1.86
A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Exp Neurol (2007) 1.82
Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol (2003) 1.67
The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol (1997) 1.66
Vigabatrin in GABA metabolism disorders. Lancet (1989) 1.51
Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Ann Neurol (2006) 1.47
Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology. J Inherit Metab Dis (2007) 1.41
GABAB receptor: a site of therapeutic benefit. Curr Opin Pharmacol (2005) 1.38
Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res (2006) 1.37
From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci (2004) 1.31
gamma-Aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comp Biochem Physiol A Physiol (1995) 1.29
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat Genet (2001) 1.28
Neurotransmitters and neuromodulators during early human development. Early Hum Dev (2001) 1.24
Absence seizures in succinic semialdehyde dehydrogenase deficient mice: a model of juvenile absence epilepsy. Pharmacol Biochem Behav (2004) 1.24
Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology (2009) 1.23
Gamma-aminobutyric acid-transaminase deficiency: a newly recognized inborn error of neurotransmitter metabolism. Neuropediatrics (1984) 1.21
Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta (1981) 1.19
Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development. BMC Dev Biol (2008) 1.19
Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev (2011) 1.16
Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther (2002) 1.13
The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem (1999) 1.11
SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol (2004) 1.10
A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis (2010) 1.10
Interactions between taurine and ethanol in the central nervous system. Amino Acids (2002) 1.10
Ketone bodies in epilepsy. J Neurochem (2012) 1.10
Excitatory GABA in rodent developing neocortex in vitro. J Neurophysiol (2008) 1.09
Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men. J Inherit Metab Dis (2009) 1.08
Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis (1995) 1.08
Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol (2003) 1.05
Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency. Neurobiol Dis (2004) 1.04
Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors (2005) 1.00
Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clin Chim Acta (1983) 0.99
Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia (2008) 0.95
Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). J Inherit Metab Dis (1996) 0.95
Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brain. Mol Genet Metab (2006) 0.94
Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase. J Neurochem (2002) 0.93
Oxidation of 4-hydroxy-2-nonenal by succinic semialdehyde dehydrogenase (ALDH5A). J Neurochem (2003) 0.93
Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth. J Biol Chem (2011) 0.91
Liver-directed adenoviral gene transfer in murine succinate semialdehyde dehydrogenase deficiency. Mol Ther (2004) 0.91
Treatment of mild cognitive impairment (MCI). Curr Alzheimer Res (2009) 0.91
Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem (2000) 0.91
Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia (1995) 0.90
Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain. Neurochem Res (2005) 0.89
Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim Biophys Acta (2008) 0.89
Inhibition of glutamate decarboxylase activity by 3-mercaptopropionic acid has different time course in the immature and adult rat brains. Neurosci Lett (1997) 0.89
GABAB-ergic motor cortex dysfunction in SSADH deficiency. Neurology (2012) 0.89
Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia (2002) 0.87
Gamma hydroxybutyrate in the monkey. I. Electroencephalographic, behavioral, and pharmacokinetic studies. Neurology (1978) 0.87
Enzymatic and immunologic identification of succinic semialdehyde dehydrogenase in rat and human neural and nonneural tissues. J Neurochem (1995) 0.87
Effect of long-term vigabatrin administration on the immature rat brain. Epilepsia (2000) 0.86
Vigabatrin therapy in patient with succinic semialdehyde dehydrogenase deficiency. Lancet (1989) 0.85
Visual field defects and other ophthalmological disturbances associated with vigabatrin. Drug Saf (2001) 0.84
The effect of 3-mercaptopropionate, an inhibitor of glutamate decarboxylase, on the levels of GABA and other amino acids, and on presynaptic inhibition in the rat cuneate nucleus. Neuropharmacology (1978) 0.84
The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1(-/-) mice. Biochim Biophys Acta (2009) 0.84
Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects? Epilepsy Res (2010) 0.83
Selective involvement of the globus pallidus and dentate nucleus in succinic semialdehyde dehydrogenase deficiency. Pediatr Radiol (2002) 0.83
Inhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivation. Mol Biosyst (2010) 0.82
Mechanism of inactivation and identification of sites of modification of ornithine aminotransferase by 4-aminohex-5-ynoate. Biochemistry (1991) 0.82
Circadian distribution of generalized tonic-clonic seizures associated with murine succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Epilepsy Behav (2008) 0.81
MRI findings in succinic semialdehyde dehydrogenase deficiency. Neuropediatrics (2000) 0.81
Taurine-transporter gene knockout-induced changes in GABA(A), kainate and AMPA but not NMDA receptor binding in mouse brain. Anat Embryol (Berl) (2005) 0.81
Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. Eur J Paediatr Neurol (2012) 0.80
Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency. JIMD Rep (2011) 0.80
Monitoring gamma-hydroxybutyric acid levels in succinate-semialdehyde dehydrogenase deficiency. Ann Neurol (2004) 0.80
SGS-742 Novartis. Curr Opin Investig Drugs (2005) 0.79
Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency. JIMD Rep (2012) 0.78
Interrelationships between ornithine, glutamate, and GABA. II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain. Neurochem Res (1988) 0.78
L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (1986) 0.78
Effect of L-cycloserine on cellular responses mediated by macrophages and T cells. Biol Pharm Bull (2007) 0.78
[Succinic semialdehyde dehydrogenase deficiency: decrease in 4-OH-butyric acid levels with low doses of vigabatrin]. An Pediatr (Barc) (2009) 0.77
Diazepam antagonizes GABAmimetics in rats with spontaneous petit mal-like epilepsy. Eur J Pharmacol (1985) 0.77
Reduced parietal activation in cervical dystonia after parietal TMS interleaved with fMRI. Clin Neurol Neurosurg (2012) 0.77
4-Hydroxybutyric aciduria: clinical findings and vigabatrin therapy. J Inherit Metab Dis (1993) 0.76
Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria. Eur J Pediatr (1992) 0.76
4-Hydroxybutyric aciduria. Brain Dev (1994) 0.75
Gamma-hydroxybutyric acid. N Engl J Med (2005) 5.81
Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet (2004) 4.08
Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress. J Biol (2007) 2.70
Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol (2010) 2.52
Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clin Chem (2004) 2.35
Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med (2006) 2.28
Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem (2003) 2.15
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
Quantitation of gamma-hydroxybutyric acid in dried blood spots: feasibility assessment for newborn screening of succinic semialdehyde dehydrogenase (SSADH) deficiency. Mol Genet Metab (2013) 2.06
Mutations in the AUH gene cause 3-methylglutaconic aciduria type I. Hum Mutat (2003) 1.86
A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Exp Neurol (2007) 1.82
Catabolism of 4-hydroxyacids and 4-hydroxynonenal via 4-hydroxy-4-phosphoacyl-CoAs. J Biol Chem (2009) 1.80
Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis (2012) 1.78
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol (2003) 1.67
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics (2003) 1.64
IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science (2010) 1.63
Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol (2012) 1.62
Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab (2011) 1.61
High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am J Hum Genet (2004) 1.55
A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci U S A (2008) 1.54
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol (2011) 1.53
The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology (2013) 1.51
Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania. Characterization of gene deletion mutants. J Biol Chem (2004) 1.49
Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain (2010) 1.47
Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Ann Neurol (2006) 1.47
Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat (2003) 1.42
Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol (2003) 1.41
Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab (2011) 1.40
Disease-related metabolites in culture medium of fibroblasts from patients with D-2-hydroxyglutaric aciduria, L-2-hydroxyglutaric aciduria, and combined D/L-2-hydroxyglutaric aciduria. Clin Chem (2003) 1.40
Uveitis and white matter abnormalities in pediatric sarcoidosis. Arch Neurol (2010) 1.39
Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res (2006) 1.37
Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med (2007) 1.32
From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci (2004) 1.31
The pentose phosphate pathway is a metabolic redox sensor and regulates transcription during the antioxidant response. Antioxid Redox Signal (2011) 1.31
Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol Psychiatry (2003) 1.29
X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28. Am J Hum Genet (2002) 1.27
Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1. Am J Hum Genet (2007) 1.27
Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat (2007) 1.26
Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. Mol Genet Metab (2004) 1.26
Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol (2003) 1.22
Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest (2011) 1.19
Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development. BMC Dev Biol (2008) 1.19
Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. Am J Hum Genet (2004) 1.18
Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev (2011) 1.16
Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects. Clin Chem Lab Med (2007) 1.16
5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med (2005) 1.15
Hypothalamic hamartomas and seizures: distinct natural history of isolated and Pallister-Hall syndrome cases. Epilepsia (2005) 1.15
Metabolic reconfiguration precedes transcriptional regulation in the antioxidant response. Nat Biotechnol (2009) 1.14
Status epilepticus in a neonate treated with pyridoxine because of a familial recurrence risk for antiquitin deficiency: pyridoxine toxicity? Dev Med Child Neurol (2011) 1.14
Adenosine kinase deficiency disrupts the methionine cycle and causes hypermethioninemia, encephalopathy, and abnormal liver function. Am J Hum Genet (2011) 1.14
Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther (2002) 1.13
A novel gamma-hydroxybutyrate dehydrogenase: identification and expression of an Arabidopsis cDNA and potential role under oxygen deficiency. J Biol Chem (2003) 1.13
Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy. Arch Neurol (2011) 1.12
Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr (2008) 1.12
Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J Nucl Med (2012) 1.12
Quantification of sugar phosphate intermediates of the pentose phosphate pathway by LC-MS/MS: application to two new inherited defects of metabolism. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.12
An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat (2010) 1.11
A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis (2010) 1.10
Intracellular S-adenosylhomocysteine increased levels are associated with DNA hypomethylation in HUVEC. J Mol Med (Berl) (2005) 1.10
Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. Am J Hum Genet (2013) 1.09
Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype. J Inherit Metab Dis (2013) 1.09
Inherited disorders of neurotransmitters in children and adults. Clin Biochem (2005) 1.09
Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Mol Genet Metab (2002) 1.09
Epilepsy imaging study guideline criteria: commentary on diagnostic testing study guidelines and practice parameters. Epilepsia (2011) 1.09
Profiling of pentose phosphate pathway intermediates in blood spots by tandem mass spectrometry: application to transaldolase deficiency. Clin Chem (2003) 1.09
Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. J Pediatr (2006) 1.09
5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry (2007) 1.09
Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance. Antioxid Redox Signal (2011) 1.08
Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab (2005) 1.08
Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum. Pediatrics (2003) 1.07
X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Hum Genet (2006) 1.06
Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev (2004) 1.06
Characterization of atypical language activation patterns in focal epilepsy. Ann Neurol (2014) 1.05
Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med (2006) 1.05
Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL gene. Hum Mutat (2008) 1.04
L-2-Hydroxyglutaric aciduria: pattern of MR imaging abnormalities in 56 patients. Radiology (2009) 1.04
Metabolism of lysine in alpha-aminoadipic semialdehyde dehydrogenase-deficient fibroblasts: evidence for an alternative pathway of pipecolic acid formation. FEBS Lett (2010) 1.03
Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism. Mol Cell Biol (2002) 1.02
Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem (2010) 1.02
An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1). Ann Neurol (2007) 1.02
The Arabidopsis her1 mutant implicates GABA in E-2-hexenal responsiveness. Plant J (2007) 1.01
Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol (2009) 1.01
Investigations by mass isotopomer analysis of the formation of D-2-hydroxyglutarate by cultured lymphoblasts from two patients with D-2-hydroxyglutaric aciduria. FEBS Lett (2004) 1.00
Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch Dis Child (2006) 1.00